Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%

Jared Holz, Mizuho healthcare sector strategist, joins ‘Squawk Box’ to discuss the impact of Novo Nordisk’s weight-loss drug Wegovy cuts risk of heart attack or stroke by 20%, the obesity drug market at large and what it means for pharmaceutical companies, and more.